EP Patent

EP2286840A3 — Treatment of obesity and related diseases

Assigned to Amylin Pharmaceuticals LLC · Expires 2013-09-04 · 13y expired

What this patent protects

Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.

USPTO Abstract

Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.

Drugs covered by this patent

Patent Metadata

Patent number
EP2286840A3
Jurisdiction
EP
Classification
—
Expires
2013-09-04
Drug substance claim
No
Drug product claim
No
Assignee
Amylin Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.